If we were talking constant dollar, which is all we should be talking about, they came in at the high end of their raised guidance.

I can't get to it in time.

While executive management transitions bring new risks, and timing of the announcement is a bit surprising, we view the injection of new management blood favorably and believe the moves will be beneficial to Cardinal longer term.

If an investor pulled out of the space because of this, they don't understand what they are invested in.

This is exactly what the companies were hired to do in the first place. Drugs are not perfectly safe.

This was good profitability on very good revenue growth.